

Apremilast (Otezla) costs $5,000-$6,800/month without insurance. Learn how to save with copay cards, patient assistance programs, and discount strategies in 2026.
Let's not sugarcoat it: Apremilast (brand name Otezla) is expensive. Without insurance, you're looking at approximately $5,000 to $6,800 per month for a 30-day supply. That's $60,000 to $81,600 per year.
For a medication that treats plaque psoriasis, psoriatic arthritis, and Behçet's disease, the cost barrier can feel as challenging as the conditions themselves. But there are real ways to reduce what you pay — sometimes to $0. Here's every option available in 2026.
Here's the pricing landscape:
These prices make Apremilast one of the more expensive oral medications for psoriatic disease. And with no generic available in the U.S. until approximately 2028-2029, there's currently no lower-cost version to turn to.
This is the single most impactful savings program for Apremilast. If you have commercial health insurance:
If your insurance requires prior authorization and you're waiting for approval:
This program is particularly valuable because PA processing for Apremilast commonly takes 1-4 weeks, and you shouldn't have to delay treatment during that time.
Traditional discount cards (GoodRx, SingleCare, RxSaver, etc.) have limited utility for Apremilast. Here's why:
That said, if you're paying cash, it's still worth checking:
For most patients, manufacturer programs will provide significantly more savings than discount cards.
For patients who are uninsured or underinsured and cannot afford Apremilast:
This program is the best option for patients who are uninsured or whose insurance doesn't cover Apremilast at all.
NeedyMeds (needymeds.org) maintains a database of patient assistance programs and can help you identify additional resources for Apremilast and other medications. They also offer a free drug discount card.
RxAssist (rxassist.org) is another comprehensive database of pharmaceutical patient assistance programs. Search for Apremilast to find current programs and eligibility requirements.
If you're struggling with insurance denials or coverage issues, the Patient Advocate Foundation (patientadvocate.org) provides free case management services to help navigate insurance appeals and financial assistance.
The newer extended-release formulation (Otezla XR, 75 mg once daily) may have different formulary placement on some insurance plans. In some cases, one formulation may have a lower copay than the other. Ask your pharmacy benefits team or insurance company about both options.
Apremilast is typically placed on a specialty tier (Tier 4 or 5) on most formularies. Some plans have accumulator or maximizer programs that limit the value of manufacturer copay cards. Understanding your plan's specifics can help you plan ahead:
If your specialty pharmacy and insurance plan allow it, filling a 90-day supply instead of a 30-day supply can sometimes reduce per-fill copays and reduce the number of times you deal with the refill process.
If your copay is unreasonably high even with insurance, you can:
Some states and nonprofit organizations offer additional assistance:
Medicare patients face unique challenges with Apremilast:
If you're on Medicare, contact Medicare at 1-800-633-4227 or visit medicare.gov to check eligibility for Extra Help.
Here's your action plan based on your insurance situation:
If you have commercial insurance:
If you have Medicare:
If you're uninsured:
No one should have to skip a medication that works because of cost. Apremilast's price tag is steep, but the savings infrastructure around it is robust — especially through Amgen's manufacturer programs. The key is knowing what's available and applying early.
Start with Amgen SupportPlus (1-833-442-6436), check availability on Medfinder, and don't accept the first price you see. With the right approach, most patients can access Apremilast at a fraction of the retail cost — or even for free.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.